D
David D.F. Ma
Researcher at University of New South Wales
Publications - 183
Citations - 10362
David D.F. Ma is an academic researcher from University of New South Wales. The author has contributed to research in topics: Transplantation & Bone marrow. The author has an hindex of 44, co-authored 174 publications receiving 9484 citations. Previous affiliations of David D.F. Ma include Royal Free Hospital & Royal Adelaide Hospital.
Papers
More filters
Journal ArticleDOI
CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group
Michael Pfreundschuh,Lorenz Trümper,Anders Österborg,Ruth Pettengell,Marek Trneny,Kevin Imrie,David D.F. Ma,Devinder Gill,Jan Walewski,Pier Luigi Zinzani,Rolf A. Stahel,Stein Kvaløy,Ofer Shpilberg,Ulrich Jaeger,Mads Hansen,Tuula Lehtinen,Armando López-Guillermo,Claudia Corrado,Adriana Scheliga,Noel Milpied,Myriam Mendila,Michelle Rashford,Evelyn Kuhnt,Markus Loeffler +23 more
TL;DR: Rituximab added to six cycles of CHOP is an effective treatment for young patients with good-prognosis diffuse large-B-cell lymphoma and the definition of two prognostic subgroups allows for a more refined therapeutic approach for these patients.
Journal ArticleDOI
Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era
Christian Gisselbrecht,Bertram Glass,Nicolas Mounier,Devinder Gill,David C. Linch,Marek Trneny,André Bosly,Nicolas Ketterer,Ofer Shpilberg,Hans Hagberg,David D.F. Ma,Josette Brière,Craig H. Moskowitz,Norbert Schmitz +13 more
TL;DR: It is found that patients with early relapses after rituximab-containing first-line therapy have a poor prognosis, with no difference between the effects of R-ICE and R-DHAP.
Journal ArticleDOI
Rituximab (Anti-CD20 Monoclonal Antibody) for the Treatment of Patients With Relapsing or Refractory Aggressive Lymphoma: A Multicenter Phase II Study
B. Coiffier,Corinne Haioun,Nicolas Ketterer,Andreas Engert,H. Tilly,David D.F. Ma,Peter Johnson,Andrew Lister,M. Feuring Buske,John Radford,R. Capdeville,Volker Diehl,Felix Reyes +12 more
TL;DR: In this first trial of rituximab in DLCL and MCL, patients experienced a significant clinical activity with a low toxicity and should be tested in combination with chemotherapy in such patients.
Journal ArticleDOI
The majority of circulating platelet-derived microparticles fail to bind annexin V, lack phospholipid-dependent procoagulant activity and demonstrate greater expression of glycoprotein Ib
TL;DR: Compared the antigenic characteristics and phospholipid-dependent procoagulant activity of annexin V positive and -negative subpopulations of platelet-derived microparticles, a significant correlation between Annexin V binding and XACT was found, suggesting that annexinV binding was a true reflection of procogulantactivity.
Journal ArticleDOI
Etoposide in acute nonlymphocytic leukemia. Australian Leukemia Study Group
J. F. Bishop,Ray M. Lowenthal,Douglas E. Joshua,Jane P. Matthews,D Todd,R. Cobcroft,M. G. Whiteside,Henry M. Kronenberg,David D.F. Ma,Anthony J. Dodds +9 more
TL;DR: Induction and consolidation therapy intensified with etoposide resulted in significantly improved remission duration but not survival, and in older patients, 7-3-7 was more toxic, with significantly more severe [World Health Organization (WHO) grade 3 or 4] stomatitis and no additional clinical benefit.